Sanli Pharmaceutical: Planning to issue stocks to specific investors to raise funds of no more than 700 million yuan.

Sanli Pharmaceutical announced that the company plans to issue A-shares to specific investors, raising a total of up to 700 million yuan. After deducting issuance expenses, the funds will be used to supplement working capital and repay bank loans. As of the end of the first quarter of 2026, the company's interest-bearing liabilities totaled 797 million yuan, with significant short-term debt pressures. The intended recipient of this issuance is the proposed establishment of Guizhou Cenli Technology Co., Ltd., in which Zhang Hai intends to hold a 100% stake and subscribe in cash. Once the funds are raised, it will enhance the company's capital strength and risk resistance capabilities, benefiting both the company and all shareholders.